Eli Lilly (LLY) recently entered a collaboration with Gate Bioscience to develop molecular gate therapeutics, a move that ...

Eli Lilly (LLY) recently received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its ...

In 2022, over 1 billion people were affected by obesity, driving innovation in therapeutic advancements. Emerging treatments focus on appetite contro ...

The sale agreement will see Eli Lilly pay up to $1bn to buy SiteOne, ... The acquisition adds to Eli Lilly’s pain pipeline, which includes four candidates. A Phase I trial (ACTRN12624000642583) ...

LLY’s Zacks Rank. Eli Lilly currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.. Only $1 to See All Zacks' Buys and Sells ...

On May 16, Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA-based gene therapies for sensorineural hearing loss, with milestone payments exceeding $1.3 billion.

Eli Lilly and Co. announced plans on Tuesday to acquire private biotechnology company San Francisco-based SiteOne Therapeutics Inc. in a deal worth up to $1 billion.

Eli Lilly is further expanding its RNA medicine strategy by tapping South Korea’s Rznomics for a $1.3 billion biobucks deal focused on treating hearing loss.. The centerpiece of the agreement is ...

INDIANAPOLIS — Indianapolis-based pharmaceutical giant Eli Lilly and Company will invest up to $250 million as part of an expanded partnership with Purdue University announced Friday, May 9. The ...

Eli Lilly LLY 1.34 % increase; green up pointing triangle agreed to acquire Verve Therapeutics VERV-0.37 % decrease; red down pointing triangle for about $1 billion upfront, adding a potential ...